Sign inCreate account

Report workspace tools

NCT05446584RECRUITINGanonymous

Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History

Sponsor

Source record

University of Texas Southwestern Medical Center

Phase

Source record

Phase 2

Modality

AI-normalized

medical device

Target

AI-normalized

High Definition Transcranial Direct Current Stimulation (HD-tDCS) targeting neural circuits associated with memory and cognitive function.

Indication / condition

AI-normalized

Mild Cognitive Impairment

Intervention

Source record

High Definition Transcranial Direct Current Stimulation

Source & freshness

Source record

NCT ID

NCT05446584

Original source

ClinicalTrials.gov

Source last updated

May 06, 2026

Ingested at

Jun 12, 2026

Internal sync

Jun 12, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05446584

Title

Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History

Sponsor

University of Texas Southwestern Medical Center

Status

RECRUITING

Phase

Phase 2

Condition raw

Mild Cognitive Impairment, Amnestic Mild Cognitive Disorder, Amnestic Mild Cognitive Impairment, Mild Traumatic Brain Injury, Concussion, Brain

Condition normalized

Mild Cognitive Impairment, Amnestic Mild Cognitive Disorder, Amnestic Mild Cognitive Impairment, Mild Traumatic Brain Injury, Concussion, Brain

Modality raw

medical device

Modality normalized

medical device

Target raw

High Definition Transcranial Direct Current Stimulation (HD-tDCS) targeting neural circuits associated with memory and cognitive function.

Target normalized

High Definition Transcranial Direct Current Stimulation (HD-tDCS) targeting neural circuits associated with memory and cognitive function.

Interventions

High Definition Transcranial Direct Current Stimulation

Public preview

Source record

The clinical trial, sponsored by the University of Texas Southwestern Medical Center, investigates the relationship between amnestic mild cognitive impairment (aMCI) and mild traumatic brain injury (mTBI) using HD-tDCS. Given the increasing prevalence of cognitive disorders in aging populations, this study addresses a significant unmet medical need. The findings could inform future therapeutic strategies and biomarker development, potentially positioning the sponsor as a leader in cognitive impairment research. The market for cognitive enhancement and neurostimulation devices is growing, with increasing interest from both pharmaceutical and medical device companies. Competitive implications include the potential for partnerships or acquisitions based on successful outcomes, particularly if the study identifies novel biomarkers or effective interventions.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT05446584

Status

RECRUITING

Phase

Phase 2

Sponsor

University of Texas Southwestern Medical Center

Executive brief

Investment-Ready Snapshot

The clinical trial, sponsored by the University of Texas Southwestern Medical Center, investigates the relationship between amnestic mild cognitive impairment (aMCI) and mild traumatic brain injury (mTBI) using HD-tDCS. Given the increasing prevalence of cognitive disorders in aging populations, this study addresses a significant unmet medical need. The findings could inform future therapeutic strategies and biomarker development, potentially positioning the sponsor as a leader in cognitive impairment research. The market for cognitive enhancement and neurostimulation devices is growing, with increasing interest from both pharmaceutical and medical device companies. Competitive implications include the potential for partnerships or acquisitions based on successful outcomes, particularly if the study identifies novel biomarkers or effective interventions.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 06, 2026
Internal syncJun 12, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05446584

Indication

Mild Cognitive Impairment

Modality

medical device

Target

High Definition Transcranial Direct Current Stimulation (HD-tDCS) targeting neural circuits associated with memory and cognitive function.

Intervention

High Definition Transcranial Direct Current Stimulation

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.